)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
UCB (UCB) investor relations material
UCB H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary31 Jul, 2025
Executive summary
Achieved 26% year-over-year net sales growth in H1 2025, with revenue reaching €3.32–€3.5B, driven by strong product launches and five key growth drivers.
Strategic investments in pipeline, manufacturing (notably a $2B–$5B US greenfield project), and patient access underpin future growth.
Upgraded full-year guidance for revenue, EBITDA margin, and core EPS based on robust H1 performance.
Recognized for sustainability, maintaining top sector ESG rankings.
Clinical pipeline advanced with positive results in multiple indications and initiation of several Phase 3 programs.
Financial highlights
Net sales reached €3.32B in H1 2025, up 26% year-over-year, with BIMZELX® sales quadrupling to nearly €800M.
Adjusted EBITDA rose 58% to €1.33B, with margin expanding to 29.6% from 23% in H1 2024.
Adjusted gross margin improved to 79%, driven by favorable product mix.
Core EPS increased 69% to €3.53 per share.
Operating expenses grew 15%, below net sales growth, reflecting continued investment in launches and R&D.
Outlook and guidance
Upgraded 2025 revenue guidance to at least €7B, EBITDA margin to at least 30%, and core EPS to at least €7.25.
Expect continued strong volume growth for BIMZELX® and effectiveness of US access strategy.
Anticipate less strong momentum in H2, with some H1 tailwinds not repeating and ongoing pricing pressure on Cimzia.
Currency headwinds, notably USD depreciation, expected to impact net sales by -3% for the full year, but EBITDA largely protected by hedging.
Continued investments planned in global launches and R&D pipeline.
Explain the updated 2025 financial guidance.
Assess BIMZELX's performance across indications.
Discuss the progress of bepranemab in Alzheimer's.
Assess HS adoption vs. Novartis' estimates.
What's the rationale for tax reorganization?
How will UCB maximize Galvokimig asset?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next UCB earnings date
H2 202526 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
UCB SA is a global biopharmaceutical company specializing in the discovery and development of innovative medicines and solutions for severe neurological and immunological disorders. The company's main areas of focus include treatments for conditions such as epilepsy, Parkinson's disease, and various immunological diseases. UCB operates through its biopharmaceutical segment, which develops, manufactures, and markets these therapies. The company is headquartered in Brussels, Belgium, and its shares are listed on the Euronext Brussels.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage